Adverse effect · Ziconotide

How common is delivery burden with Ziconotide?

A
Grade A — established in humansLabel · effect size: moderate · adverse
Short answerEstablished in humans. Label point the same way: a moderate effect. Ziconotide is given only by continuous intrathecal infusion through an implanted or external pump — a surgical commitment with the infection and device risks that accompany it, and the reason it is a last-line therapy rather than an alternative to oral analgesia.

What the studies show

Ziconotide is given only by continuous intrathecal infusion through an implanted or external pump — a surgical commitment with the infection and device risks that accompany it, and the reason it is a last-line therapy rather than an alternative to oral analgesia.

Several well-run randomised trials in people, pointing the same way. You can plan around this. It still says nothing about whether the effect is worth the side effects for you.

  1. 1
    Prialt (ziconotide) intrathecal infusion prescribing information.DailyMed, read 29 Oct 2026Boxed warning, contraindication in pre-existing psychosis, intrathecal route, CSF terminal half-life about 4.6 hours, and the 25-amino-acid structure with three disulfide bonds.

In context

Ziconotide is a synthetic copy of a 25-amino-acid peptide from the venom of the cone snail Conus magus, approved as Prialt in 2004 for severe chronic pain in people who need intrathecal therapy. It blocks N-type calcium channels in the spinal cord — a mechanism unrelated to opioids, with no tolerance and no dependence. In its cancer and AIDS pain trial, pain scores improved 53.1% against 18.1% on placebo. It carries a boxed warning for severe psychiatric and neurological effects.

Ziconotide is approved (rx). Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Ziconotide proven to cause delivery burden?
Yes, as far as human trials can show it: Label. LYO grades this outcome A.
What studies are behind the grade?
Ziconotide is given only by continuous intrathecal infusion through an implanted or external pump — a surgical commitment with the infection and device risks that accompany it, and the reason it is a last-line therapy rather than an alternative to oral analgesia.
Is Ziconotide approved for this?
Ziconotide is an approved medicine (Approved (Rx)); whether this particular outcome is a licensed indication is stated on the compound page's regulation section.

Other outcomes for Ziconotide

Written and maintained by LYO Research — how pages are written and checked. Reviewed 29 October 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →